全文获取类型
收费全文 | 112293篇 |
免费 | 8861篇 |
国内免费 | 1698篇 |
专业分类
耳鼻咽喉 | 411篇 |
儿科学 | 1951篇 |
妇产科学 | 2144篇 |
基础医学 | 18533篇 |
口腔科学 | 3730篇 |
临床医学 | 19159篇 |
内科学 | 19496篇 |
皮肤病学 | 1255篇 |
神经病学 | 9310篇 |
特种医学 | 3339篇 |
外国民族医学 | 8篇 |
外科学 | 8790篇 |
综合类 | 7778篇 |
现状与发展 | 20篇 |
一般理论 | 4篇 |
预防医学 | 6811篇 |
眼科学 | 1390篇 |
药学 | 8466篇 |
66篇 | |
中国医学 | 1105篇 |
肿瘤学 | 9086篇 |
出版年
2024年 | 303篇 |
2023年 | 4991篇 |
2022年 | 7259篇 |
2021年 | 7893篇 |
2020年 | 8310篇 |
2019年 | 4752篇 |
2018年 | 4371篇 |
2017年 | 4290篇 |
2016年 | 4706篇 |
2015年 | 5209篇 |
2014年 | 9592篇 |
2013年 | 7170篇 |
2012年 | 6307篇 |
2011年 | 5632篇 |
2010年 | 5756篇 |
2009年 | 5186篇 |
2008年 | 2846篇 |
2007年 | 2987篇 |
2006年 | 2518篇 |
2005年 | 1979篇 |
2004年 | 1627篇 |
2003年 | 1537篇 |
2002年 | 1473篇 |
2001年 | 1518篇 |
2000年 | 1245篇 |
1999年 | 1291篇 |
1998年 | 1053篇 |
1997年 | 816篇 |
1996年 | 875篇 |
1995年 | 827篇 |
1994年 | 659篇 |
1993年 | 514篇 |
1992年 | 618篇 |
1991年 | 600篇 |
1990年 | 571篇 |
1989年 | 536篇 |
1988年 | 538篇 |
1987年 | 471篇 |
1986年 | 397篇 |
1985年 | 309篇 |
1984年 | 399篇 |
1983年 | 325篇 |
1982年 | 326篇 |
1981年 | 333篇 |
1980年 | 276篇 |
1979年 | 201篇 |
1978年 | 190篇 |
1977年 | 184篇 |
1976年 | 167篇 |
1974年 | 134篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
12.
13.
目的了解长春西部地区过敏原特异性IgE分布情况。方法应用免疫印迹法检测1 258例患者的19种吸入性及食物性过敏原特异性IgE抗体,统计过敏原结果及种类。结果 1 258例患者,检出至少一种特异性IgE阳性率为34.0%。男性阳性率为33.5%;女性阳性率为34.5%。男女间阳性率差异无统计学意义(P> 0.05)。吸入性过敏原阳性率由高到低依次为:普通豚草14.2%、艾蒿11.4%、屋尘螨/粉尘螨8.1%、猫毛3.8%、狗上皮2.4%、柳树/杨树/榆树2.1%,屋尘1.6%、蟑螂1.6%、点青霉/分枝孢霉/烟曲霉/交链孢霉1.2%、葎草1.1%。食物性过敏原阳性率由高到低依次为:鸡蛋白2.9%、鳕鱼/龙虾/扇贝2.7%、牛奶2.3%、黄豆1.9%、蟹1.5%、虾1.3%、牛肉1.2%、花生1.0%、羊肉0.8%。混合过敏达到了相当高的比例。结论长春西部地区吸入性过敏原以普通豚草、艾蒿和屋尘螨/粉尘螨为主;食物性过敏原以鸡蛋白、鳕鱼/龙虾/扇贝、牛奶为主,明确过敏原,对过敏性患者的预防和治疗有重大意义。 相似文献
14.
Béla Nagy Zsolt Bene Zsolt Fejes Sonya L. Heltshe David Reid Nicola J. Ronan Yvonne McCarthy Daniel Smith Attila Nagy Elizabeth Joseloff György Balla János Kappelmayer Milan Macek Scott C. Bell Barry J. Plant Margarida D. Amaral István Balogh 《Journal of cystic fibrosis》2019,18(2):271-277
Background
We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.Methods
In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).Results
After 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r?=??0.5376; P?<?.001 and r?=??0.3285; P?<?.001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P?<?.001).Conclusions
This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy. 相似文献15.
16.
17.
Social phobia, fear of negative evaluation and harm avoidance. 总被引:1,自引:0,他引:1
M Faytout J Tignol J Swendsen D Grabot B Aouizerate J P Lépine 《European psychiatry》2007,22(2):75-79
This naturalistic, prospective investigation examined the role of fear of negative evaluation and the personality trait of harm avoidance in the anxiety levels of treated social phobia patients. One hundred and fifty-seven patients with DSM-IV social phobia were assessed before starting treatment and were then followed for up to two years. As expected, greater fear of negative evaluation and higher scores of harm avoidance were associated with greater anxiety at the 6 month follow-up, and harm avoidance remained a significant predictor at 24 months. However, no evidence was found for an interaction between the personality and cognitive variables examined. The findings are discussed in terms of the relative independence of these factors, as well as their potential implications for the treatment of this disorder. 相似文献
18.
G. Kahlmeter D. F. J. Brown F. W. Goldstein A. P. MacGowan J. W. Mouton I. Odenholt A. Rodloff C-J. Soussy M. Steinbakk F. Soriano O. Stetsiouk 《Clinical microbiology and infection》2006,12(6):501-503
The main objectives of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are to harmonise breakpoints for antimicrobial agents in Europe, and to act as the breakpoint committee for the European Medicines Agency (EMEA) during the registration of new antimicrobial agents. Detailed EUCAST procedures for harmonising and setting breakpoints for antimicrobial agents are available on the EUCAST website. Beginning with the current issue, a series of EUCAST Technical Notes will be published in CMI, based on the rationale documents produced by EUCAST for each of the antimicrobial agents studied, with the aim of highlighting important background information underlying decisions on breakpoints made by EUCAST. 相似文献
19.
20.
Firouzan Massoomi Pharm.D. John Savage Pharm.D. Christopher J. Destache Pharm.D. 《Pharmacotherapy》1993,13(1):46-59
Omeprazole is a member of a new class of substituted benzimidazoles. These agents inhibit the proton pump in the gastric parietal cell, blocking the final step in the gastric acid secretory pathway. Omeprazole has been investigated for the treatment of gastric ulcer, duodenal ulcer, gastroesophageal reflux, and various hypersecretory states. The prolonged inhibition of gastric acid secretion allows for once-daily dosing in patients with peptic ulcer disease and gastroesophageal reflux, and once- or twice-daily dosing in patients with Zollinger-Ellison syndrome. Compared with currently available therapies, omeprazole is well tolerated and demonstrates a more rapid ulcer healing rate. It is superior to conventional therapies in the treatment of Zollinger-Ellison syndrome. Side effects are infrequent when the drug is used for the short-term management of ulcers. 相似文献